APO Research
Talk to an analyst

APO RESEARCH · REPORT

APOL1 Mediated Kidney Disease

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global APOL1 Mediated Kidney Disease Market Outlook and Growth Opportunities 2026

30 December 2025199 pages

Choose your research edition.

Industry ResearchAPOL1 Mediated Kidney Disease Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal APOL1 Mediated Kidney Disease Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal APOL1 Mediated Kidney Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal APOL1 Mediated Kidney Disease Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal APOL1 Mediated Kidney Disease Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global APOL1 Mediated Kidney Disease market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for APOL1 Mediated Kidney Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for APOL1 Mediated Kidney Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for APOL1 Mediated Kidney Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the APOL1 Mediated Kidney Disease market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the APOL1 Mediated Kidney Disease market include Teva Pharmaceuticals, Novartis, ZyVersa Therapeutics, Vertex Pharmaceuticals, Travere Therapeutics, Ionis Pharmaceuticals, GlaxoSmithKline and ChemoCentryx, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global APOL1 Mediated Kidney Disease market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of APOL1 Mediated Kidney Disease and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents APOL1 Mediated Kidney Disease revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global APOL1 Mediated Kidney Disease market.

APOL1 Mediated Kidney Disease Segment by Company

Teva Pharmaceuticals

Novartis

ZyVersa Therapeutics

Vertex Pharmaceuticals

Travere Therapeutics

Ionis Pharmaceuticals

GlaxoSmithKline

ChemoCentryx

APOL1 Mediated Kidney Disease Segment by Type

Small Molecule

Gene Modification

Nucleic Acid Therapies

Others

APOL1 Mediated Kidney Disease Segment by Application

Chronic Kidney Disease

End Stage Kidney Disease

APOL1 Mediated Kidney Disease Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global APOL1 Mediated Kidney Disease status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the APOL1 Mediated Kidney Disease key companies, revenue, market share, and recent developments.

3. To split the APOL1 Mediated Kidney Disease breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions APOL1 Mediated Kidney Disease market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify APOL1 Mediated Kidney Disease significant trends, drivers, influence factors in global and regions.

6. To analyze APOL1 Mediated Kidney Disease competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global APOL1 Mediated Kidney Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of APOL1 Mediated Kidney Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of APOL1 Mediated Kidney Disease.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global APOL1 Mediated Kidney Disease industry.

Chapter 3: Detailed analysis of APOL1 Mediated Kidney Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of APOL1 Mediated Kidney Disease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of APOL1 Mediated Kidney Disease in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. APOL1 Mediated Kidney Disease Industry Trends Table 2. APOL1 Mediated Kidney Disease Industry Drivers Table 3. APOL1 Mediated Kidney Disease Industry Opportunities and Challenges Table 4. APOL1 Mediated Kidney Disease Industry Restraints Table 5. Global APOL1 Mediated Kidney Disease Revenue by Company (US$ Million) & (2021-2026) Table 6. Global APOL1 Mediated Kidney Disease Revenue Share by Company (2021-2026) Table 7. Global APOL1 Mediated Kidney Disease Company Ranking, (2024-2026) & (US$ Million) Table 8. Global APOL1 Mediated Kidney Disease Key Company Manufacturing Base & Headquarters Table 9. Global APOL1 Mediated Kidney Disease Company, Product Type & Application Table 10. Global APOL1 Mediated Kidney Disease Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global APOL1 Mediated Kidney Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Small Molecule Table 15. Significant Companies of Gene Modification Table 16. Significant Companies of Nucleic Acid Therapies Table 17. Significant Companies of Others Table 18. Global APOL1 Mediated Kidney Disease Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global APOL1 Mediated Kidney Disease Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global APOL1 Mediated Kidney Disease Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global APOL1 Mediated Kidney Disease Sales Value Share by Type (2021-2026) Table 22. Global APOL1 Mediated Kidney Disease Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Chronic Kidney Disease Table 24. Significant Companies of End Stage Kidney Disease Table 25. Global APOL1 Mediated Kidney Disease Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global APOL1 Mediated Kidney Disease Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global APOL1 Mediated Kidney Disease Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global APOL1 Mediated Kidney Disease Sales Value Share by Application (2021-2026) Table 29. Global APOL1 Mediated Kidney Disease Sales Value Share by Application (2027-2032) Table 30. Global APOL1 Mediated Kidney Disease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global APOL1 Mediated Kidney Disease Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global APOL1 Mediated Kidney Disease Sales Value Share by Region (2021-2026) Table 33. Global APOL1 Mediated Kidney Disease Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global APOL1 Mediated Kidney Disease Sales Value Share by Region (2027-2032) Table 35. Global APOL1 Mediated Kidney Disease Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global APOL1 Mediated Kidney Disease Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global APOL1 Mediated Kidney Disease Sales Value Market Share by Country (2021-2026) Table 38. Global APOL1 Mediated Kidney Disease Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global APOL1 Mediated Kidney Disease Sales Value Market Share by Country (2027-2032) Table 40. Teva Pharmaceuticals Company Information Table 41. Teva Pharmaceuticals Business Overview Table 42. Teva Pharmaceuticals APOL1 Mediated Kidney Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Teva Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio Table 44. Teva Pharmaceuticals Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis APOL1 Mediated Kidney Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Novartis APOL1 Mediated Kidney Disease Product Portfolio Table 49. Novartis Recent Development Table 50. ZyVersa Therapeutics Company Information Table 51. ZyVersa Therapeutics Business Overview Table 52. ZyVersa Therapeutics APOL1 Mediated Kidney Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. ZyVersa Therapeutics APOL1 Mediated Kidney Disease Product Portfolio Table 54. ZyVersa Therapeutics Recent Development Table 55. Vertex Pharmaceuticals Company Information Table 56. Vertex Pharmaceuticals Business Overview Table 57. Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio Table 59. Vertex Pharmaceuticals Recent Development Table 60. Travere Therapeutics Company Information Table 61. Travere Therapeutics Business Overview Table 62. Travere Therapeutics APOL1 Mediated Kidney Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Travere Therapeutics APOL1 Mediated Kidney Disease Product Portfolio Table 64. Travere Therapeutics Recent Development Table 65. Ionis Pharmaceuticals Company Information Table 66. Ionis Pharmaceuticals Business Overview Table 67. Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio Table 69. Ionis Pharmaceuticals Recent Development Table 70. GlaxoSmithKline Company Information Table 71. GlaxoSmithKline Business Overview Table 72. GlaxoSmithKline APOL1 Mediated Kidney Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. GlaxoSmithKline APOL1 Mediated Kidney Disease Product Portfolio Table 74. GlaxoSmithKline Recent Development Table 75. ChemoCentryx Company Information Table 76. ChemoCentryx Business Overview Table 77. ChemoCentryx APOL1 Mediated Kidney Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. ChemoCentryx APOL1 Mediated Kidney Disease Product Portfolio Table 79. ChemoCentryx Recent Development Table 80. Research Programs/Design for This Report Table 81. Authors List of This Report Table 82. Secondary Sources Table 83. Primary Sources List of Figures Figure 1. APOL1 Mediated Kidney Disease Product Image Figure 2. Global APOL1 Mediated Kidney Disease Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global APOL1 Mediated Kidney Disease Market Size (2021-2032) & (US$ Million) Figure 4. Global APOL1 Mediated Kidney Disease Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Small Molecule Image Figure 8. Gene Modification Image Figure 9. Nucleic Acid Therapies Image Figure 10. Others Image Figure 11. Global APOL1 Mediated Kidney Disease Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global APOL1 Mediated Kidney Disease Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global APOL1 Mediated Kidney Disease Sales Value Share by Type (2021-2032) Figure 14. Chronic Kidney Disease Image Figure 15. End Stage Kidney Disease Image Figure 16. Global APOL1 Mediated Kidney Disease Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global APOL1 Mediated Kidney Disease Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global APOL1 Mediated Kidney Disease Sales Value Share by Application (2021-2032) Figure 19. Global APOL1 Mediated Kidney Disease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global APOL1 Mediated Kidney Disease Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America APOL1 Mediated Kidney Disease Sales Value (2021-2032) & (US$ Million) Figure 22. North America APOL1 Mediated Kidney Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe APOL1 Mediated Kidney Disease Sales Value (2021-2032) & (US$ Million) Figure 24. Europe APOL1 Mediated Kidney Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific APOL1 Mediated Kidney Disease Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific APOL1 Mediated Kidney Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America APOL1 Mediated Kidney Disease Sales Value (2021-2032) & (US$ Million) Figure 28. South America APOL1 Mediated Kidney Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa APOL1 Mediated Kidney Disease Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa APOL1 Mediated Kidney Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecule
  • Gene Modification
  • Nucleic Acid Therapies
  • Others
Applications
  • Chronic Kidney Disease
  • End Stage Kidney Disease
Companies covered
  • Teva Pharmaceuticals
  • Novartis
  • ZyVersa Therapeutics
  • Vertex Pharmaceuticals
  • Travere Therapeutics
  • Ionis Pharmaceuticals
  • GlaxoSmithKline
  • ChemoCentryx

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global APOL1 Mediated Kidney Disease Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global APOL1 Mediated Kidney Disease Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 APOL1 Mediated Kidney Disease Market Dynamics
  1. 2.1 APOL1 Mediated Kidney Disease Industry Trends
  2. 2.2 APOL1 Mediated Kidney Disease Industry Drivers
  3. 2.3 APOL1 Mediated Kidney Disease Industry Opportunities and Challenges
  4. 2.4 APOL1 Mediated Kidney Disease Industry Restraints
3 APOL1 Mediated Kidney Disease Market by Company
  1. 3.1 Global APOL1 Mediated Kidney Disease Company Revenue Ranking in 2025
  2. 3.2 Global APOL1 Mediated Kidney Disease Revenue by Company (2021-2026)
  3. 3.3 Global APOL1 Mediated Kidney Disease Company Ranking (2024-2026)
  4. 3.4 Global APOL1 Mediated Kidney Disease Company Manufacturing Base and Headquarters
  5. 3.5 Global APOL1 Mediated Kidney Disease Company Product Type and Application
  6. 3.6 Global APOL1 Mediated Kidney Disease Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global APOL1 Mediated Kidney Disease Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 APOL1 Mediated Kidney Disease Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 APOL1 Mediated Kidney Disease Market by Type
  1. 4.1 APOL1 Mediated Kidney Disease Type Introduction
  2. 4.1.1 Small Molecule
  3. 4.1.2 Gene Modification
  4. 4.1.3 Nucleic Acid Therapies
  5. 4.1.4 Others
  6. 4.2 Global APOL1 Mediated Kidney Disease Sales Value by Type
  7. 4.2.1 Global APOL1 Mediated Kidney Disease Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global APOL1 Mediated Kidney Disease Sales Value by Type (2021-2032)
  9. 4.2.3 Global APOL1 Mediated Kidney Disease Sales Value Share by Type (2021-2032)
5 APOL1 Mediated Kidney Disease Market by Application
  1. 5.1 APOL1 Mediated Kidney Disease Application Introduction
  2. 5.1.1 Chronic Kidney Disease
  3. 5.1.2 End Stage Kidney Disease
  4. 5.2 Global APOL1 Mediated Kidney Disease Sales Value by Application
  5. 5.2.1 Global APOL1 Mediated Kidney Disease Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global APOL1 Mediated Kidney Disease Sales Value by Application (2021-2032)
  7. 5.2.3 Global APOL1 Mediated Kidney Disease Sales Value Share by Application (2021-2032)
6 APOL1 Mediated Kidney Disease Regional Value Analysis
  1. 6.1 Global APOL1 Mediated Kidney Disease Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global APOL1 Mediated Kidney Disease Sales Value by Region (2021-2032)
  3. 6.2.1 Global APOL1 Mediated Kidney Disease Sales Value by Region: 2021-2026
  4. 6.2.2 Global APOL1 Mediated Kidney Disease Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America APOL1 Mediated Kidney Disease Sales Value (2021-2032)
  7. 6.3.2 North America APOL1 Mediated Kidney Disease Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe APOL1 Mediated Kidney Disease Sales Value (2021-2032)
  10. 6.4.2 Europe APOL1 Mediated Kidney Disease Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific APOL1 Mediated Kidney Disease Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific APOL1 Mediated Kidney Disease Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America APOL1 Mediated Kidney Disease Sales Value (2021-2032)
  16. 6.6.2 South America APOL1 Mediated Kidney Disease Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa APOL1 Mediated Kidney Disease Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa APOL1 Mediated Kidney Disease Sales Value Share by Country, 2025 VS 2032
7 APOL1 Mediated Kidney Disease Country-level Value Analysis
  1. 7.1 Global APOL1 Mediated Kidney Disease Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global APOL1 Mediated Kidney Disease Sales Value by Country (2021-2032)
  3. 7.2.1 Global APOL1 Mediated Kidney Disease Sales Value by Country (2021-2026)
  4. 7.2.2 Global APOL1 Mediated Kidney Disease Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt APOL1 Mediated Kidney Disease Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt APOL1 Mediated Kidney Disease Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt APOL1 Mediated Kidney Disease Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceuticals
  2. 8.1.1 Teva Pharmaceuticals Company Information
  3. 8.1.2 Teva Pharmaceuticals Business Overview
  4. 8.1.3 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio
  6. 8.1.5 Teva Pharmaceuticals Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis APOL1 Mediated Kidney Disease Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis APOL1 Mediated Kidney Disease Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 ZyVersa Therapeutics
  14. 8.3.1 ZyVersa Therapeutics Company Information
  15. 8.3.2 ZyVersa Therapeutics Business Overview
  16. 8.3.3 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Revenue and Gross Margin (2021-2026)
  17. 8.3.4 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Product Portfolio
  18. 8.3.5 ZyVersa Therapeutics Recent Developments
  19. 8.4 Vertex Pharmaceuticals
  20. 8.4.1 Vertex Pharmaceuticals Company Information
  21. 8.4.2 Vertex Pharmaceuticals Business Overview
  22. 8.4.3 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio
  24. 8.4.5 Vertex Pharmaceuticals Recent Developments
  25. 8.5 Travere Therapeutics
  26. 8.5.1 Travere Therapeutics Company Information
  27. 8.5.2 Travere Therapeutics Business Overview
  28. 8.5.3 Travere Therapeutics APOL1 Mediated Kidney Disease Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Travere Therapeutics APOL1 Mediated Kidney Disease Product Portfolio
  30. 8.5.5 Travere Therapeutics Recent Developments
  31. 8.6 Ionis Pharmaceuticals
  32. 8.6.1 Ionis Pharmaceuticals Company Information
  33. 8.6.2 Ionis Pharmaceuticals Business Overview
  34. 8.6.3 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio
  36. 8.6.5 Ionis Pharmaceuticals Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline APOL1 Mediated Kidney Disease Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline APOL1 Mediated Kidney Disease Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 ChemoCentryx
  44. 8.8.1 ChemoCentryx Company Information
  45. 8.8.2 ChemoCentryx Business Overview
  46. 8.8.3 ChemoCentryx APOL1 Mediated Kidney Disease Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ChemoCentryx APOL1 Mediated Kidney Disease Product Portfolio
  48. 8.8.5 ChemoCentryx Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst